Henry Schein

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgicals, diagnostic tests, infection-control products and vitamins. The Technology & Value-Added Services segment offers financial on a non-recourse basis, network and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Henry Schein reports solid Q4 performance and anticipates growth

Henry Schein's Q4 performance showcased growth amidst challenges, with a strategic focus on core margin expansion and strong performance in dental specialties. While facing challenges from declining PPE sales and supply chain issues, the company sees opportunities in stable dental markets and continued growth in operating income. Overall, the company remains optimistic about its outlook for 2023.

Henry Schein reports strong Q1 earnings, eyes growth through acquisitions

Henry Schein's Q1 2023 earnings call highlighted strong financial performance across its dental, medical, and Technology and Value-Added Services businesses. While facing challenges from declining PPE and COVID-19 test kit sales, the company remains optimistic about growth opportunities through acquisitions and stable business segments.

Henry Schein reports solid Q2 results, eyes growth opportunities

Henry Schein's Q2 performance was driven by strong dental sales, while facing challenges from declining PPE and COVID test kit sales. The company is focused on strategic acquisitions and expanding product offerings, with opportunities in technology and specialty products driving growth.

Henry Schein navigates post-cyber incident challenges, focuses on recovery

Henry Schein faced challenges from a cybersecurity incident impacting operations but showcased resilience and recovery efforts across its business segments.
Strategic initiatives focused on customer retention, operational efficiency, and cybersecurity response highlight the company's commitment to long-term growth and stability.
Despite challenges in specific segments and cybersecurity spending variables, Henry Schein's focus on recovery, cost-cutting, and customer trust positions it for future opportunities.
The company's emphasis on digital channels, stable medical demand, and strategic cost-cutting measures underscores its adaptability and strategic vision for sustained growth.

Henry Schein reports resilient Q4 performance and outlines 2024 guidance

Henry Schein's Q4 2023 performance reflects resilience amidst challenges, with a strategic focus on technology, global sales, and recovery post-cyber incident. The company's 2024 outlook includes managing residual cyber impacts and pursuing growth opportunities.

Henry Schein reports solid Q1 earnings, eyes market share expansion

Henry Schein's Q1 performance reflects resilience and growth across key segments, with a focus on market share expansion and profitability. While facing challenges in dental consumables and pricing stability, the company is leveraging opportunities in product portfolio expansion and market positioning. Strategic acquisitions and recovery efforts post-cyber incident are driving competitive strength and customer loyalty.

Henry Schein reports mixed Q2 performance, focuses on cost savings

Henry Schein navigated challenges from a cyber incident, with mixed performance across segments in Q2 2024.
Strong sales growth in dental specialties, focus on cost savings, and resilience in technology services were highlights.
The company's strategic initiatives, financial guidance update, and confidence in future prospects were key takeaways from the call.

Henry Schein excels in Q3 with strategic growth initiatives

Henry Schein's Q3 performance reflects strong market positioning and strategic execution, driving growth across key business segments.
While facing challenges such as LCI sales decline, the company's focus on operational efficiency and cost management remains a priority.
With increased sales guidance, ongoing restructuring initiatives, and strategic capital allocation plans, Henry Schein is poised for continued success and expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins. The Technology and Value-Added Services segment offers financial on a non-recourse basis, network, and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) reminds its customers across the eastern United States that the Henry Schein Customer Assistance Hotline is open for dentists and physicians who may experience operational, logistical, or financial issues as a result of damage caused Tropical Storm Henri. The toll-free number for all Henry Schein customers is 800-999-9729. The hotline is open 24/7, with real-time assistance available from Team Schein Members from 8 a.m. to 6 p.m

Henry Schein Opens Customer Assistance Hotline in Response to Tropical Storm Henri

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein announces new $1 billion credit facility.

Henry Schein Announces New $1 Billion Credit Facility

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein is partnering with NGOs to provide health care products to aid Haitian earthquake victims and is opening its disaster relief fund.

Henry Schein Partners With NGOs to Provide Health Care Products to Aid Haitian Earthquake Victims and Opens Disaster Relief Fund

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein Opens Customer Assistance Hotline in Response to the Dixie Fire in Northern California

Henry Schein Opens Customer Assistance Hotline in Response to the Dixie Fire in Northern California

Strong performance by the Dental, Medical & Technology and Value-Added Services segments is driving Henry Schein's (HSIC) top line.

Here's Why You Should Add Henry Schein (HSIC) to Your Portfolio

Henry Schein, Inc. (HSIC) CEO Stanley Bergman on Q2 2021 Results - Earnings Call Transcript

Strengthening demand in the global dental and medical markets drove Henry Schein's (HSIC) revenues in the second quarter.

Henry Schein (HSIC) Q2 Earnings Top Estimates, 2021 EPS View Up

Henry Schein (HSIC) delivered earnings and revenue surprises of 16.84% and 2.74%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Henry Schein (HSIC) Q2 Earnings and Revenues Beat Estimates

Henry Schein Inc (NASDAQ: HSIC) posts Q2 net sales of $2.97 billion, beating the consensus of $2.89 billion, up 76.2% Y/Y when a significant number of dental and medical practices suspended activity due to the COVID-19 pandemic.  Compared with the pre-pandemic Q2 of 2019, sales were up 21.2% and included 15.2% internal growth in local currencies, 4.2% growth from acquisitions, and 1.8% growth related to foreign currency exchange.

Henry Schein Sees FY21 EPS Below Consensus, But Q2 Earnings Beat Expectations

Shares of Henry Schein (NASDAQ:HSIC) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were up 0.00% year over year to $1.11, which beat the estimate of $0.97.

Henry Schein: Q2 Earnings Insights

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. reports record second-quarter 2021 financial results from continuing operations.

Henry Schein Reports Record Second-Quarter 2021 Financial Results From Continuing Operations

Henry Schein (NASDAQ:HSIC) announces its next round of earnings this Tuesday, August 03. Here is Benzinga's everything-that-matters guide for this Tuesday's Q2 earnings announcement.

A Preview Of Henry Schein's Earnings

Henry Schein's (HSIC) PPE sales from medical business are likely to have maintained momentum in Q2. Also, global recovery trends of its dental business are expected to reflect on Q2 results.

What's in Store for Henry Schein (HSIC) in Q2 Earnings?

Cooper Companies

HSIC vs. COO: Which Stock Is the Better Value Option?

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its second quarter 2021 financial results before the stock market opens on Tuesday, August 3, 2021, and will provide a live webcast of its earnings conference call on the same day beginning at 10:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Bo

Henry Schein to Webcast Second Quarter 2021 Conference Call on Tuesday, August 3, 2021 at 10:00 A.M. ET

Henry Schein (HSIC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Henry Schein (HSIC) is Poised to Beat Earnings Estimates Again

Align Technology

Patterson Companies

DENTSPLY SIRONA

Dental stocks like Henry Schein (HSIC), Align Technology (ALGN), Straumann Holding (SAUHF) and DENTSPLY SIRONA (XRAY) are expected to continue their run over the next few months.

Dental Space Gains Momentum in 2021: 4 Stocks to Invest in

BellRing Brands Inc

Harrow Health Inc

West Pharmaceutical Services

Stocks like Henry Schein (HSIC), BellRing Brands (BRBR), Harrow Health (HROW) and West Pharmaceuticals Services (WST) are solid low-beta picks with strong fundamentals.

Bet on 4 Low-Beta MedTech Stocks to Ride the Choppy Market

Heritage-Crystal Clean

Vale S.A.

United States Steel

Top Ranked Growth Stocks to Buy for July 1st

National Vision Hlds

Grab these three top stocks, EYE, WST and HSIC, which continue to show promise amid the pandemic and can turn out to be wise investment choices for 2021.

3 Best MedTech Growth Stocks to Bet On in 2021 Amid Pandemic

Target

Top Ranked Growth Stocks to Buy for June 29th

Maravai LifeSciences Holdings

Here are four MedTech stocks, HSIC, BRBR, MRVI and EYE, with favorable Zacks Rank and stellar growth parameters.

4 Safe MedTech Bets Before Delta Strain Disrupts the Market Again

Macy's

Tennant

Top Ranked Growth Stocks to Buy for June 24th

AutoNation

Top Ranked Growth Stocks to Buy for June 23rd

Phibro Animal Health

UnitedHealth Group

Fundamentally-sound stocks like Henry Schein (HSIC), UnitedHealth Group (UNH) and Phibro Animal Health (PAHC) are trading at a discount and make great picks for the long term.

News for Henry Schein Stock (HSIC)